Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 photoimmunotherapy + pembrolizumab vs standard of care in first-line locoregional recurrent HNSCC
2025-523017-28-00Phase 3Authorised
- Sponsor
- Rakuten Medical, Inc.
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing ASP-1929 photoimmunotherapy + pembrolizumab with Standard of care (pembrolizumab ± chemotherapy) (2 arms). Primary endpoint: Overall Survival. Planned start Sep 2026; status: authorised.
02
Drugs
cetuximab sarotalocan sodiumpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-523017-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523017-28-00.